Vobarilizumab
Based on 1 Customer Validation
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.9%
- CAS No.: 1628814-88-9
- Masse moléculaire:25.69 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Isotype
VH-VH'
Species Reactivity
Human
IC50 & Target
IL-6Ra & ALB
In Vitro
Vobarilizumab shows a preferential binding affinity for sIL-6R compared with mIL-6R[2].
Vobarilizumab (0-10 nM) blocks the interaction of recombinant hIL-6 to recombinant hsIL-6R[3].
Vobarilizumab (0-100 nM) blocks proliferation of the TF-1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Vobarilizumab (0.4-10 mg/kg, i.v.) shows a prolonged exposure through binding to serum albumin in cynomolgus monkeys[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:hIL-6-induced inflammation in cynomolgus monkey[3]
-
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Inhibited the acute phase response parameters: plasma levels of C-reactive protein (CRP), fibrinogen and platelets.
-
Animal Model:Cynomolgus monkeys[3]
-
Dosage:0.4 mg/kg, 2 mg/kg, or 10 mg/kg
-
Administration:Intravenous injection (i.v.)
-
Result:Pharmacokinetic parameters of Vobarilizumab
dose (mg/kg) T1/2 dominant (day) AUCinf (μg/day/mL) CL (mL/day/kg) Vss (mL/kg) 0.4 (i.v.) 1.73 16.3 24.8 42.8 2 (i.v.) 5.0 193 10.4 53.7 10 (i.v.) 6.61 1136 9 82.7
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
VH-VH'
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IL-6R Protein (ECD, His Tag) can bind Vobarilizumab. The EC50 for this effect is 2.34 ng/mL. -
Immobilized Serum Albumin/ALB Protein, Human (HEK293, His-Avi, HY-P78393) can bind Vobarilizumab. The EC50 for this effect is 183.3 ng/mL.
Chemical Information
-
CAS No. 1628814-88-9
-
Appearance Liquid
-
Masse moléculaire 25.69 kDa
-
Color Colorless to light yellow
-
SMILES
[Vobarilizumab]
-
Synonyms
ALX-0061
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-759. [Content Brief]
[3]. Van Roy M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17(1):135. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vobarilizumab Related Classifications
HY-P99385 Related Classifications
Powered by Bioz